Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
|Articles|December 24, 2012
Supplements and Featured Publications
- Improving Clinical and Managed Care Outcomes in Rheumatoid arthritis: a Focus on Comparative Effecti
- Volume 18
- Issue 13 Suppl
Improving Clinical and Managed Care Outcomes in Rheumatoid Arthritis: A Focus on Comparative Effectiveness of Current Treatments
Advertisement
Instructions
After reading “Improving Clinical and Managed Care Outcomes in Rheumatoid Arthritis: A Focus on Comparative Effectiveness of Current Treatments,” complete the program evaluation and select the single best answer to each of the posttest questions.
A statement of continuing education credit will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher on the posttest.
Articles in this issue
almost 14 years ago
Comparative Effectiveness of Current Treatments for Rheumatoid Arthritisalmost 14 years ago
Implications for Managed Care and Specialty Pharmacy in Rheumatoid ArthritisAdvertisement
Related to this article
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
NPC researchers examined questions about how these policies could affect patients, pharmacies, and providers.
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
3
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
4
Iberdomide Regimen Cuts RRMM Progression Risk by 51%, Trial Finds
5